0000000000398013

AUTHOR

Piergiorgio Malagoli

0000-0002-6181-6922

showing 3 related works from this author

Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

2019

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and…

AdultMalemedicine.medical_specialtyHealth Knowledge Attitudes PracticeAdolescentdisease awarenessMEDLINEDermatologyDisease.030207 dermatology & venereal diseases03 medical and health sciencesDiagnostic Self EvaluationYoung Adult0302 clinical medicineHealth caremedicineEffective treatmentHumansHidradenitis suppurativa030212 general & internal medicineMass MediaYoung adultIntensive care medicineChildAdolescent; Adult; Aged; Child; Cysts; Diagnostic Self Evaluation; Female; Health Education; Health Knowledge Attitudes Practice; Hidradenitis Suppurativa; Humans; Male; Mass Media; Middle Aged; Social Media; Young Adult; CommunicationHealth EducationAgedPracticebusiness.industryCystsInflammatory skin diseaseHealth KnowledgeCommunicationhidradenitis suppurativadisease awareness communication hidradenitis suppurativaMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesCystAttitudesHealth educationFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREESocial MediaHuman
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Additional file 1 of A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA obs…

2021

Additional file 1.

Data_FILES
researchProduct